Antithrombotic Strategy in Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention

Area of Science:

• Cardiology
• Pharmacology
• Clinical Medicine

Background:

• Managing antithrombotic therapy for patients with atrial fibrillation (AF) after percutaneous coronary intervention (PCI) is complex.
• Traditional warfarin-based triple therapy is associated with high rates of major bleeding (up to 12% annually).

Purpose of the Study:

• To review the evidence supporting dual antithrombotic therapy with non-vitamin K antagonist oral anticoagulants (NOACs) in AF patients post-PCI.
• To emphasize the potential for reduced bleeding complications.

Main Methods:

• Review of clinical trial data, focusing on the WOEST trial and subsequent studies.
• Analysis of efficacy and safety outcomes for dual versus triple antithrombotic regimens.

Main Results:

• Dual therapy without aspirin demonstrated significantly lower bleeding risks compared to triple therapy.
• Thromboembolic event rates were similar between dual and triple therapy groups.
• NOAC-based dual therapy is emerging as an optimal regimen.

Conclusions:

• Dual therapy, particularly with NOACs, represents a favorable strategy for AF patients undergoing PCI.
• This approach balances the need for thromboembolic event prevention with a substantial reduction in bleeding risk.